{
    "ucits": true,
    "type": "ETF",
    "derivatives": false,
    "swaps": false,
    "leverage": false,
    "inverse": false,
    "replication_method": "physical",
    "complex_factors": "",
    "classification": "non-complex",
    "supporting_data": "The asset is a UCITS ETF, which under MiFID II is automatically presumed non-complex due to the strict regulatory framework governing UCITS funds[1]. The ETF aims to replicate the NASDAQ 100 Index by physical replication, holding the underlying equity securities in similar proportions, which is a straightforward and transparent method supporting non-complex classification[extracted text]. The use of derivatives is limited to foreign exchange forward contracts for currency hedging purposes, which are employed for efficient portfolio management (EPM) and do not form an integral part of the investment objective or strategy[extracted text]. This limited derivative use for hedging does not trigger complexity under MiFID II rules, as derivatives are not central to the ETF's performance replication and counterparty risk is minimal and well-managed[1][extracted text]. There is no indication of embedded derivatives, leverage beyond UCITS limits, or complex structured products such as CLOs within the ETF's holdings[extracted text]. Securities lending is used as a secondary feature to generate additional income but is well-managed under UCITS rules and does not dominate the risk profile[extracted text]. The underlying index, NASDAQ 100, is a transparent, well-documented equity index, further supporting non-complexity[extracted text]. The risk profile reflects market volatility typical of equity investments and does not imply structural complexity[extracted text]. Therefore, based on the MiFID II Article 25(4)(a)(iv) presumption for UCITS, the physical replication method, limited derivative use for EPM, absence of embedded derivatives or leverage, and transparent index, this UCITS ETF is classified as non-complex under MiFID II. Firms distributing this ETF would not be required to perform an appropriateness assessment for non-advised sales, consistent with ESMA and CESR guidance[1][2]."
}